Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,106.11 -0.97 (-0.09%)

Streaming Delayed Price Updated: 11:59 AM EDT, Jun 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

99 100 Next >

Why Is Eli Lilly Stock Gaining Today? ↗

April 01, 2026

Eli Lilly shares surged after FDA approval of its oral obesity drug Foundayo, boosting growth prospects in the weight-loss market.

Via Benzinga

Eli Lilly (LLY) Stock Trades Up, Here Is Why

April 01, 2026

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 4.7% in the afternoon session after the FDA approved Foundayo (orforglipro...

Via StockStory

Eli Lilly Jumps After Winning FDA Approval For Obesity Pill ↗

April 01, 2026

Eli Lilly stock jumped midday Wednesday after the FDA approved its weight-loss pill, now called Foundayo.

Via Investor's Business Daily

Centessa Pharmaceuticals Agrees To Eli Lilly Acquisition At 40% Premium ↗

April 01, 2026

Centessa Pharma to be acquired by Eli Lilly for $8B. Analyst downgrades rating. Deal includes $6.3B in cash and potential $1.5B in milestones.

Via Benzinga

Stock Of The Day: Where Will Eli Lilly Turn? ↗

April 01, 2026

Eli Lilly (LLY) shares rallied after finding support at a formed resistance level. They may hit resistance at a former support level.

Via Benzinga

Eli Lilly & Co (NYSE:LLY): A Prime Dividend Growth Candidate Backed by Strong Profitability ↗

March 30, 2026

Via Chartmill

1 Reason This $900 Stock Could Announce a Split in 2026 ↗

April 01, 2026

This pharmaceutical giant appears well positioned for a potential stock split in 2026.

Via The Motley Fool

Hasbro's Q1 2026 Earnings: What to Expect

April 01, 2026

Hasbro is expected to announce its first-quarter results soon, and analysts are projecting a single-digit decline in its EPS.

Via Barchart.com

Topics ETFs Workforce

What to Expect From Nasdaq's Q1 2026 Earnings Report

April 01, 2026

Nasdaq will release its first-quarter earnings soon, and analysts anticipate a double-digit bottom-line growth.

Via Barchart.com

Topics ETFs Workforce

Willis Towers Watson's Q1 2026 Earnings: What to Expect

April 01, 2026

Willis Towers Watson will release its first-quarter earnings soon, and analysts anticipate a double-digit bottom-line growth.

Via Barchart.com

Topics Artificial Intelligence ETFs Workforce

Wall Street Ends a Rough Quarter With Its Best Day, Iran Hope Ignites the Rally ↗

April 01, 2026

Via Chartmill

Why Centessa Stock Soared Today ↗

March 31, 2026

A pharma giant wants to buy the innovative drug developer.

Via The Motley Fool

Is This Weight Loss Drug Stock a Buy After a New Approval? ↗

March 31, 2026

This little-known biotech company has a different strategy than the established weight-loss drug market leaders. But is it likely to be successful?

Via The Motley Fool

Eli Lilly Expands Into Sleep Medicine With Centessa Buyout ↗

March 31, 2026

Eli Lilly to acquire Centessa Pharmaceuticals for $6.3B. CNTA stock surges 45% as Lilly expands its neuroscience and sleep medicine pipeline.

Via Benzinga

Eli Lilly Is Bringing AI-Developed Drugs to Market. Should You Buy LLY Stock to Profit?

March 31, 2026

Eli Lilly has expanded its partnership with Insilico Medicine to bring AI developed medicine into global market.

Via Barchart.com

Topics Artificial Intelligence

The Orexin Gold Rush: Deep Dive into Eli Lilly’s $7.8 Billion Acquisition of Centessa Pharmaceuticals

March 31, 2026

Today, March 31, 2026, the biotechnology landscape has been fundamentally reshaped. Eli Lilly and Company (NYSE: LLY) has officially announced a definitive agreement to acquire Centessa Pharmaceuticals...

Via Finterra

Topics Economy Initial Public Offering Intellectual Property

The $1 Trillion Goliath: Why Eli Lilly’s $6.3B Centessa Bet Defines the Future of Neuroscience

March 31, 2026

Date: March 31, 2026 Introduction In the spring of 2026, the global pharmaceutical landscape is increasingly defined by the gravitational pull of a single entity: Eli Lilly and Company (NYSE: LLY)....

Via Finterra

Topics Economy Intellectual Property

Eli Lilly To Buy Centessa Pharma For Up To $7.8 Billion; Centessa Shares Skyrocket ↗

March 31, 2026

The takeover fills a glaring hole in Eli Lilly's pipeline, says one analyst.

Via Investor's Business Daily

2 Healthcare Stocks Wall Street Analysts Say Could Rally 60% or More ↗

March 31, 2026

There are some tempting bargains if you know where to look.

Via The Motley Fool

Merck Just Made a Big Bet on a New Cancer Growth Engine ↗

March 31, 2026

Via MarketBeat

Stock Market Today, March 30: High Oil Prices Drive Risk-Off Sentiment, Nasdaq Falls 0.7% ↗

March 30, 2026

Inflation and growth worries impacted tech stocks as investors question AI price tags today, March 30, 2026.

Via The Motley Fool

Topics Artificial Intelligence Bonds Economy

Eli Lilly's CEO Says This Could Be a Game Changer for Its Business ↗

March 30, 2026

The healthcare stock may not be running out of growth catalysts anytime soon.

Via The Motley Fool

Nervous About the Market? 3 Vanguard ETFs That Were Made for Times Like These. ↗

March 30, 2026

You can sleep peacefully at night owning these Vanguard ETFs.

Via The Motley Fool

Topics Bonds ETFs Economy

Prediction: Buying Pfizer Stock Today Could Set You Up for Life ↗

March 29, 2026

Pfizer is behind Eli Lilly and Novo Nordisk in the GLP-1 race, but long-term investors shouldn't count the company out.

Via The Motley Fool

Topics Intellectual Property

Eli Lilly Secures $2.75 Billion Deal With Insilico Medicine To Bring AI-Developed Drugs To Global Market: Report ↗

March 29, 2026

Eli Lilly's deal involves an upfront payment of $115 million to Insilico, with additional payments tied to milestones.

Via Benzinga

1 Reason This Biotech Stock Could Triple Before Year-End ↗

March 29, 2026

This little-known biotech could have a big hit on its hands with VK2735, a GLP-1 weight loss drug candidate.

Via The Motley Fool

1 Reason Eli Lilly Stock Is Still a Buy ↗

March 28, 2026

Eli Lilly is much more than just a weight loss stock.

Via The Motley Fool

Topics Artificial Intelligence

Eli Lilly Shares Slip Despite Positive Eczema Trial Results: Why the Market Reacted Coolly

March 27, 2026

INDIANAPOLIS – In a move that has left some retail investors scratching their heads, shares of Eli Lilly and Company (NYSE:LLY) have trended lower this week, despite the pharmaceutical giant releasing...

Via MarketMinute

Eli Lilly vs Novo Nordisk: Which Obesity Drug Stock Is the Better Buy? ↗

March 27, 2026

It's not much of a contest right now.

Via The Motley Fool

Corporate Fortress: S&P 500 Defies Gravity with Fifth Consecutive Quarter of Double-Digit Growth

March 27, 2026

The American corporate engine has proven far more durable than even the most optimistic analysts predicted just a year ago. As of March 27, 2026, final results for the fourth quarter of 2025 have...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.